Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Physicians and patient advocates are sounding the alarm after the NIH abruptly withdrew a grant renewal application for the ...

In a US study, patients with severe eosinophilic esophagitis (EoE) by Index of Severity for EoE had poor responses to topical corticosteroid therapy.

NS Pharma, a unit of Nippon Shinyaku (OTCPK:NPNKF), said on Monday that the U.S. FDA has granted orphan drug designation to ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.

Steinhubl et al. evaluate individuals’ physiologic response to COVID-19 vaccines through continuous monitoring with a patch sensor. By creating physiologic digital twins from each individual’s ...

CSU is a chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring ... chronic rhinosinusitis with nasal polyps, eosinophilic ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...